share_log

东诚药业:关于下属公司在研产品177Lu-LNC1004获得FDA快速通道资格的公告

Dongcheng Pharmaceutical: Announcement on the subsidiary\'s product 177Lu-LNC1004 being developed to obtain FDA Fast Track qualification

SZSI ·  Oct 30, 2024 00:00
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more